title: Bevacizumab in conjunction with panretinal photocoagulation for neovascular glaucoma.
abstract: BACKGROUND
  Neovascular glaucoma (NVG) is a type of secondary angle-closure glaucoma that can result from severe retinal ischemia, such as proliferative diabetic retinopathy. Vascular endothelial growth factor (VEGF) plays a role in ocular neovascularization, which can result in NVG. The use of bevacizumab, an anti-VEGF antibody, has been shown to lead to the rapid resolution of ocular neovascularization and may be used off-label in conjunction with panretinal photocoagulation in the treatment of neovascular glaucoma.
  
  
  METHODS
  A 71-year-old man presented with neovascular glaucoma in both eyes secondary to proliferative diabetic retinopathy and was treated with both panretinal photocoagulation and an intravitreal injection of bevacizumab, which led to the rapid resolution of his iris neovascularization. A follow-up examination after 12 months showed that there was no recurrence of neovascularization.
  
  
  CONCLUSIONS
  This case shows the possible beneficial effects of bevacizumab in conjunction with panretinal photocoagulation as a treatment option for neovascular glaucoma.
authors.affiliation: Southern Arizona Veterans Affairs Health Care System, Tucson, Arizona, USA. alyon.wasik@va.gov
authors.forename: Alyon
authors.initials: A
authors.lastname: Wasik
authors.forename: Huey-Fen
authors.initials: HF
authors.lastname: Song
authors.forename: Amy
authors.initials: A
authors.lastname: Grimes
authors.forename: Carla
authors.initials: C
authors.lastname: Engelke
authors.forename: Abby
authors.initials: A
authors.lastname: Thomas
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D008028:Light Coagulation; D008297:Male; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab